Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder

Autor:	Nicholas DeMartinis, Venkatesh D. Handratta, Jayesh Kamath
Rok vydání:	2007
Předmět:	medicine.drug_class Venlafaxine Pharmacology medicine.disease Desvenlafaxine Neurology Tolerability medicine Antidepressant Major depressive disorder Neurology (clinical) Adverse effect Psychology Desvenlafaxine Succinate medicine.drug Serotonin–norepinephrine reuptake inhibitor
Zdroj:	Future Neurology. 2:361-371
ISSN:	1748-6971 1479-6708
DOI:	10.2217/14796708.2.4.361
Popis:	Venlafaxine is a serotonin–norepinephrine-reuptake inhibitor (SNRI) with a well-established efficacy, safety and tolerability profile. Desvenlafaxine succinate is the succinate salt monohydrate of O-desmethylvenlafaxine, an active metabolite of venlafaxine, and, like its parent compound, is an SNRI. A sustained-release form of desvenlafaxine succinate 100 mg/day has demonstrated efficacy for the treatment of adult major depressive disorder in large multicenter trials. Desvenlafaxine succinate has a good overall safety and tolerability profile, with adverse effects comparable with those of other SNRIs. The most frequent side effects of desvenlafaxine succinate include nausea, dry mouth, constipation, dizziness, insomnia, somnolence, anorexia and sweating. The primary advantage of the sustained-release formulation over other SNRIs based on current information is related to its minimal metabolism via the cytochrome P450 (CYP450) pathway and its minimal impact on CYP450 enzyme systems. Its low potential for drug–drug interactions may have significant clinical relevance, especially in depression associated with medical comorbidities.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::24bad6dbe78b3923cba6a1e609aa26d1 https://doi.org/10.2217/14796708.2.4.361 Zobrazit plný text záznamu